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ABSTRACT
Different mechanisms of angiogenesis and vasculogenesis are involved in the 
development of the tumor vasculature. Among them, cancer stem cells are known to 
contribute to tumor vasculogenesis through their direct endothelial differentiation. 
Here, we investigated the effect of anti-angiogenic therapy on vasculogenesis of 
cancer stem cells derived from breast and renal carcinomas. We found that all the 
anti-angiogenic approaches impaired proliferation and survival of cancer stem cells 
once differentiated into endothelial cells in vitro and reduced murine angiogenesis 
in vivo. At variance, only VEGF-receptor inhibition using the non-specific tyrosine 
kinase inhibitor Sunitinib or the anti-VEGF-receptor 2 neutralizing antibody, but not 
VEGF blockade using Bevacizumab, impaired the process of endothelial differentiation 
in vitro, suggesting a VEGF-independent mechanism. In addition, tyrosine kinase 
inhibition by Sunitinib but not VEGF blockade using the soluble VEGF trap sFlk1 
inhibited the cancer stem cell-induced vasculogenesis in vivo. Accordingly, Sunitinib 
but not Bevacizumab inhibited the induction of hypoxia-inducible factor pathway 
occurring during endothelial differentiation under hypoxia. The present results 
highlight a differential effect of VEGF-receptor blockade versus VEGF inhibition in 
tumor vascularization. VEGFR blockade inhibits the process of tumor vasculogenesis 
occurring during tumor hypoxia whereas the effect of VEGF inhibition appears 
restricted to differentiated endothelial cells.
INTRODUCTION
Tumor vascularization is a fundamental step 
for tumor growth, expansion and progression [1]. 
Recent data indicate that the tumor vasculature is quite 
heterogeneous possibly due to different mechanisms 
of angiogenesis and vasculogenesis [2]. Tumor cells 
can secrete growth factors and cytokines in order to 
recruit normal endothelial cells from adjacent vessels 
[3, 4]. Moreover, tumor endothelial cells may derive 
from an intra-tumor embryonic-like vasculogenesis 
due to differentiation of normal stem cells of 
hematopoietic origin [5]. Finally, tumor cells with 
stem cell properties, so called cancer stem cells (CSC), 
of different solid tumors may participate to tumor 
vasculogenesis by a direct endothelial differentiation 
[6–16]. The role of CSC vasculogenesis is emerging 
as an important mechanism for tumor progression, and 
selective targeting of endothelial cells generated by CSC 
in xenografted tumors was recently showed to induce 
tumor reduction and degeneration [14]. We previously 
isolated CSC and deriving clones from breast and renal 
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carcinomas that were able to differentiate into both 
epithelial and endothelial cells in vitro [15, 16]. In vivo, 
breast and renal CSC and deriving clones generated 
epithelial tumors as well as tumor vessels, indicating 
that at least a fraction of tumor vessels derived from the 
endothelial differentiation of CSC [15, 16].
Drugs that target tumor vascularization have been 
recently introduced in the clinical practice for different 
solid tumors. Anti-angiogenic therapies may directly target 
endothelial cells in the growing vasculature, as tyrosine 
kinase inhibitors do, or indirectly block the activity of 
angiogenesis inducers such as VEGF. In particular, the 
multi-tyrosine kinase inhibitors Sunitinib and Sorafenib 
directly target VEGF receptors (VEGFRs) and other non-
endothelial receptors such as CD117 and the receptors 
for Platelet Derived Growth Factor (CD140), for Colony 
Stimulating Factor 1 and for Glial cell line-Derived 
Neurotrophic Factor (RET) [17]. In addition, the anti-
VEGF mAb (Bevacizumab) potently binds to VEGF 
preventing its docking with VEGFRs [18].
These anti-angiogenic drugs are known to affect all 
the different VEGF-dependent mechanisms involved in the 
angiogenic process, such as endothelial cell proliferation, 
survival and vessel stabilization [4]. However, the effect of 
these drugs on alternative strategies of tumor vascularization, 
and in particular on the CSC-derived endothelial cells and 
on the process of their differentiation, is at present unknown.
In the present study, we set up a model of hypoxia-
induced endothelial differentiation of CSC from breast and 
renal carcinomas and we aimed to investigate the role of 
the anti-angiogenetic drugs Sunitinib and Bevacizumab 
both on CSC-derived differentiated endothelial cells and 
on the hypoxia-induced process of CSC differentiation 
into endothelial cells. Moreover, we investigated the effect 
of Sunitinib and of the soluble VEGF trap sFlk1 on CSC-
induced vasculogenesis in vivo.
RESULTS
Endothelial differentiation of breast and renal 
CSC under hypoxia
We previously isolated and characterized CSC from 
renal and breast carcinomas showing tumor-initiating 
and differentiative ability in vitro and in vivo [15, 16 and 
Supplementary Table 1]. As reported, B-CSC were able to 
grow in mammospheres, were CD44+/CD24− and showed 
absence of differentiation markers of the cell types of the 
glandular epithelium as they did not express cytokeratin-14 
and -18 [16] (Figure 1A and 1B). In analogy, CSC from renal 
carcinomas were identified as CD105+ CSC clones, grew in 
spheres and lacked expression of epithelial differentiative 
markers such as cytokeratin [15] (Figure 1A and 1B). 
Both B-CSC and R-CSC were able to differentiate into 
epithelial cells, as shown by the acquisition of cytokeratin 
in vitro, when cultured in RPMI plus 10% FCS (Figure 1B). 
In addition, they acquired endothelial cell markers when 
cultured for 14 days in the presence of a complete medium 
containing VEGF and 10% FCS [15, 16]. The absence 
of contaminating cells is supported by the clonal origin 
of the CSC lines. In the present study, to mimic the tumor 
microenvironment, we set up a protocol of endothelial 
differentiation under hypoxia (1% O2) in the absence 
of growth factors or serum. CSC cultured under this 
condition showed the ability to differentiate in vitro into 
endothelial cells. CSC acquired, after 14 days of endothelial 
differentiation, full expression of endothelial markers such 
as CD31, VEGFR2, VE-cadherin, vWF (Figure 1C) and the 
ability to organize into capillary-like structures (Figure 1C).
Anti-proliferative and cytotoxic effect of 
Sunitinib and Bevacizumab on CSC-deriving 
endothelial cells
We evaluated the effect of the anti-angiogenic drugs 
Sunitinib and Bevacizumab on CSC and CSC-derived 
endothelial cells. No effect of Sunitinib and Bevacizumab 
was observed on the proliferation of undifferentiated 
B-CSC and R-CSC (Figure 2A). Indeed, these cells did 
not express the growth factor receptors known to be 
target of Sunitinib (VEGFR1, 2 and 3, CD117, CD140; 
not shown). A slight but significant cytotoxic effect was 
observed on R-CSC at 5–10 μM Sunitinib, possibly related 
to a toxic drug effect (Figure 2B), as previously reported 
on renal cancer cells at doses higher than 5 μM (17). At 
variance, Sunitinib (5–10 μM) and Bevacizumab (25–250 
μg/ml) significantly impaired proliferation of endothelial-
differentiated CSC (Figure 2A). In addition, Sunitinib 
(1–10 μM) and Bevacizumab (25–250 μg/ml) significantly 
reduced their survival (Figure 2B). This is possibly due to 
the acquisition by differentiated cells of the expression of 
VEGFRs (Figure 1C) and not of CD117 or CD140; not 
shown. We also tested whether the response to these drugs 
on proliferation and survival was comparable to that of 
the total endothelial cell population derived from a breast 
tumor (BTEC) and of normal endothelial cells (HUVEC). 
The effect observed on endothelial-differentiated B-CSC 
was comparable to that of BTEC. In contrast, HUVEC 
showed a higher sensitivity to the anti-proliferative and 
cytotoxic effects of these drugs (Figure 2C and 2D).
Effect of Sunitinib but not of Bevacizumab on 
endothelial differentiation of CSC in vitro
We next investigated whether a chronic treatment 
with the anti-angiogenic drugs could impair the endothelial 
differentiative ability of B-CSC and R-CSC in hypoxia. 
For these experiments, the dose of 1 μM Sunitinib and 
100 μg/ml Bevacizumab was selected as non-toxic on 
CSC. As shown in Figure 3A and 3B, Sunitinib almost 
completely abolished the acquisition of the endothelial 
markers CD31, VEGFR1, 2 and 3 and Tie-2 by both 
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B-CSC and R-CSC after 14 days in differentiating 
conditions. In contrast, cells treated with Bevacizumab 
maintained the endothelial differentiative ability as shown 
by the acquisition of all endothelial markers (Figure 3A 
and 3B). This was also confirmed at mRNA level, as 
VEGFR2 and Tie-2 mRNA expression, evaluated by RT-
PCR after endothelial differentiation, was comparable to 
that in total tumor endothelial cells (BTEC) (Figure 3C). 
The endothelial markers were lacking in Sunitinib treated 
CSC, and not in Bevacizumab treated cells (Figure 3C), 
further supporting the cytofluorimetric data. In parallel, 
in the presence of Sunitinib, but not of Bevacizumab, 
CSC maintained the expression of the stem markers 
Oct4-A and Nanog, downregulated by control cells after 
endothelial differentiation (Figure 3D). Moreover, CSC 
cells differentiated in the presence of Sunitinib did not 
acquire the endothelial ability to organize in tubular-like 
structures (Figure 3E), confirming that Sunitinib inhibited 
the endothelial property of CSC. At variance, CSC 
differentiated in the presence of Bevacizumab acquired the 
ability to organize in tubular structures, as control CSC 
(Figure 3E).
Dispensable role of VEGF in endothelial 
differentiation of CSC
To further investigate the role of VEGF on the 
differentiation process of CSC, we generated B-CSC 
transfected to stably express the soluble VEGF-trap 
sFlk1 (sFLK1 cells, Figure 4B) to obtain a constant 
inhibition of endogenous/exogenous VEGF binding. 
As found for Bevacizumab, sFLK1 cells were able to 
acquire endothelial markers during differentiation both 
at protein and mRNA level (Figure 4A and 4C) while 
they lost stem cell markers in respect to undifferentiated 
CSC (Figure 4D).
Figure 1: Characterization and differentiative properties of CSC from breast and renal carcinomas. Panel A and B. B-CSC and 
R-CSC grew in spheres and were characterized as CD24−/CD44+ or CD24−/CD105+ cells, respectively (A). B-CSC and R-CSC lacked cytokeratin 
(CK) that was acquired when cultured in epithelial differentiating conditions (EPITH. DIFF.) for 14 days (D14), as compared with basal condition 
(D0) (B). Panel C. B-CSC and R-CSC cultured for 14 days (D14) in endothelial differentiating conditions under hypoxia (ENDOTH. DIFF.) 
acquired the endothelial-specific markers CD31, VEGFR2, VE-cadherin (VE-CAD) and vWF and the ability to organize into capillary-like 
structures. Original magnification: immunofluorescence staining: x400; tubulogenesis: x200. Nuclei were counterstained with Hoechst dye.
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To test the role of VEGF intracellular pathway on 
endothelial differentiation, we inhibited the activation of 
VEGFRs using the anti-VEGFR2 or the anti-VEGFR1 
neutralizing Abs. The anti-VEGFR2 neutralizing Ab 
(0.2 μg/ml) but not the anti-VEGFR1 neutralizing Ab 
(0.2 μg/ml) or an irrelevant Ab (not shown), administered 
to CSC during hypoxic endothelial differentiation, 
limited the acquisition of endothelial markers on 
CSC (Figure 4A and 4C). The lack of endothelial 
differentiation by treatment with the anti-VEGFR2 Ab, 
Figure 2: Cytotoxic effect of Bevacizumab and Sunitinib on CSC-derived endothelial cells. Panel A and B. Effect of 
1–10 μM Sunitinib (S1-S10) and of 25–250 μg/ml Bevacizumab (B25-B250) on proliferation (A) and apoptosis (B) of B-CSC and 
R-CSC before (Undiff, black columns) and after the endothelial differentiation (Diff., white columns). Panel C and D. The effect of 
Bevacizumab and Sunitinib on endothelial differentiated CSC was compared to that on total breast tumor-derived endothelial cells 
(BTEC) or on normal endothelial cells (HUVEC). Data are mean ± SD of five different experiments (A and B) or three different 
experiments (C and D). Student’s t test was performed: **= p < 0.001, *= p < 0.05 drug treated vs CTL cells.
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Figure 3: Effect of Bevacizumab and Sunitinib on the endothelial differentiation of CSC. Panel A and B. 1 μM Sunitinib 
(S1), but not 100 μg/ml Bevacizumab (B100), impaired the hypoxia-mediated endothelial differentiation of B-CSC (A) and R-CSC (B) as 
shown by the lack of acquisition of endothelial specific markers. In the representative FACS analyses, the grey area shows binding of the 
specific antibody and the dark line the isotypic control. In the lower histogram, the percentage of expression is reported. Data are mean ± SD 
of five different experiments. Student’s t test was performed: **= p < 0.001, *= p < 0.05 vs CTL. Panel C. Quantitative RT-PCR analysis 
showing the acquisition of the expression of endothelial markers VEGFR2 (VR2) and TIE-2 by B-CSC after endothelial differentiation 
(CTL) in respect to undifferentiated B-CSC (Basal). Sunitinib (1 μM, S1) but not Bevacizumab (100 μg/ml, B100) abrogated VEGFR2 and 
TIE-2 mRNA expression. Total breast tumor-derived endothelial cells (BTEC) were used as positive control of differentiation. Data were 
normalized to GAPDH mRNA and to 1 for undifferentiated CSC (Basal) and expressed as relative quantification (RQ). Data are mean ± 
SD of three different experiments. ANOVA with Newmann-Keuls’ multicomparison test was performed: *= p < 0.05 and **= p < 0.001 
vs CTL; $= p < 0.05 and $$= p < 0.001 vs Basal. Panel D. Quantitative RT-PCR analysis showing the reduction of Oct4-A and Nanog 
by CSC differentiated into endothelial cells (CTL) in respect to undifferentiated CSC (Basal). CSC differentiated in the presence of 1 μM 
Sunitinib (S1), but not of 100 μg/ml Bevacizumab (B100) maintained these markers. Data were normalized to GAPDH mRNA and to 1 for 
Basal and expressed as relative quantification (RQ). Data are mean ± SD of three different experiments. ANOVA with Newmann-Keuls’ 
multicomparison test was performed: *= p < 0.05 and **= p < 0.001 vs CTL; $= p < 0.05 and $$= p < 0.001 vs Basal. Panel E. Effect 
of Bevacizumab and Sunitinib on endothelial-differentiated CSC organization into capillary-like structures. Quantitative evaluation and 
representative micrographs show the formation of capillary-like structures by control cells (CTL) and by cells treated with 1 μM Sunitinib 
(S1) or 100 μg/ml Bevacizumab (B100). Data are expressed as the mean ± SD of the length of capillary-like structures, evaluated by the 
computer analysis system in arbitrary units (a.u.) in at least 10 different fields. Four different experiments per group were carried out in 
duplicate. Original magnification x200. Student’s t test was performed: **= p < 0.001 vs CTL.
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Figure 4: Effect of the VEGF trap sFlk1 and VEGFR blockade on CSC endothelial differentiation. Panel A. Representative 
FACS analyses showing the expression of endothelial differentiation markers by B-CSC infected with lentiviruses carrying an empty vector 
(Ctl) or the soluble VEGF trap sFlk1 (sFLK1 cells) or treated with an anti-VEGFR2 and an anti-VEGFR1 neutralizing Abs (anti-VR2 and 
anti-VR1). The grey area shows binding of the specific antibody and the dark line the isotypic control. Panel B. Western blot micrograph 
showing the presence of the soluble VEGFR2 (sVR2) in the supernatant of cells expressing the soluble VEGF trap sFlk1 (sFLK1 cells) but 
not an empty vector (Ctl). Panel C. Quantitative RT-PCR analyses showing the acquisition of the expression of VR2 and TIE-2 after 14 days 
of endothelial differentiation by Ctl, sFLK1 B-CSC and by B-CSC incubated with the anti-VR1, but not by B-CSC incubated with the anti-
VR2, during differentiation process. Data were normalized to GAPDH mRNA and to 1 for undifferentiated CSC (Basal) and expressed as 
relative quantification (RQ). Data are mean ± SD of three different experiments. ANOVA with Newmann-Keuls’ multicomparison test was 
performed: *= p < 0.05 and **= p < 0.001 vs CTL; $= p < 0.05 and $$= p < 0.001 vs Basal. Panel D. Quantitative RT-PCR analysis showing 
the expression of the stem cell markers (Oct4-A, Vimentin and Nanog) by CSC (Basal) and by B-CSC differentiated in the presence of anti-
VR2 antibody (anti-VR2). The expression of stem cell markers were significantly decreased in B-CSC differentiated into endothelial cells and 
in B-CSC differentiated into endothelial cells in the presence of anti-VEGFR1 neutralizing Ab (anti-VR1) and in sFLK1 cells compared with 
basal condition. Data were normalized to GAPDH mRNA and to 1 for undifferentiated CSC (Basal) and expressed as relative quantification 
(RQ). Data are mean ± SD of three different experiments. ANOVA with Newmann-Keuls’ multicomparison test was performed: *= p < 0.05 
and **= p < 0.001 vs CTL; $= p < 0.05 and $$= p < 0.001 vs Basal. Panel E. The percentage of VEGFR2+ cells at different time points during 
endothelial differentiation was assessed in control B-CSC cells (CTL), or in the sFLK1 cells or in cells treated with 1 μM Sunitinib (S1) or with 
an anti-VEGFR2 neutralizing Ab (anti-VR2). Data are mean ± SD of three different experiments. Student’s t test was performed: **p < 0.001 
vs CTL. Panel F. VEGFR2 Tyr951 phosphorylation was detected in B-CSC cells expressing an empty vector (CTL), or the soluble VEGF trap 
sFlk1 (sFLK1 cells) by Western blot analysis of cell lysates immunoprecipitated with an anti-VEGFR2 Ab. VEGFR2 phosphorylation levels 
are expressed as the ratio of phosphorylated VEGFR2 to total VEGFR2. Data are representative of three different experiments.
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but not with the anti-VEGFR1 Ab, was confirmed by a 
concomitant maintenance of the expression of the stem 
markers Oct4-A, Vimentin and Nanog (Figure 4D). 
VEGFR2 expression remained very low in cells treated 
with the anti-VEGFR2 antibody, but not with the VEGF 
trap sFlk1, during the whole process of differentiation 
(Figure 4E). These data suggest that CSC endothelial 
differentiation may occur independently by VEGF. On 
the contrary, VEGFR2 activation appears relevant for 
this process. This was confirmed by the phosphorylation 
of VEGFR2 in endothelial differentiated CSC both in 
control and in the presence of VEGF blockade (sFLK1 
cells, Figure 4F). These results suggest that interference 
with VEGFR2, but not with VEGFR1 or with 
VEGF itself, inhibits the endothelial differentiation of 
CSC, which is possibly due to an intracellular VEGFR2 
trans-activation.
To test the relevance of intracellular pathways possibly 
inhibited by the anti-angiogenic treatment, we evaluated 
the role of the Akt pathway. A significant activation of 
the Akt pathway was observed in CSC under endothelial 
differentiation, as early as at day 3, and maintained up to 
complete differentiation (14 days) (Supplementary Figure 
1A and 1B). However, no significant modulation of Akt 
activation was detected in cells treated with Sunitinib or 
anti-VEGFR2 or anti-VEGFR1 Abs (Supplementary Figure 
1C and 1D).
Sunitinib but not Bevacizumab impaired the 
hypoxia-induced HIF-1 alpha activation
As in our experimental setting endothelial 
differentiation required hypoxia, we also evaluated 
the effect of Sunitinib and Bevacizumab on the HIF 
pathway. When B-CSC were incubated under hypoxia 
in differentiating conditions, HIF-1 alpha but not HIF-2 
alpha was upregulated (Figure 5A). Sunitinib impaired 
HIF-1 alpha upregulation both at mRNA and protein level 
(Figure 5A and 5B). No effect of Bevacizumab on HIF-
1 alpha mRNA was observed (Figure 5A). These data 
indicate the ability of Sunitinib, and not of Bevacizumab, 
to block the hypoxia-induced intracellular pathways 
required for endothelial differentiation.
The requirement of HIF-1 alpha activation during 
the process of endothelial differentiation of B-CSC under 
hypoxia was confirmed using cells knocked-down for 
HIF-1 and/or 2 alpha. HIF-1 alpha and HIF-2 alpha double 
knocked-down CSC were generated since a compensatory 
mechanism of upregulation of HIF-1 alpha or HIF-2 alpha 
was observed in cells silenced for the other HIF isoform 
under hypoxia, (Supplementary Figure 2A and 2B). 
Indeed, CSC knocked down for both HIF-1 or 2 alpha 
significantly reduced their endothelial differentiation 
(Figure 5C and 5D). A partial reduction was observed in 
HIF-1 or 2 alpha single knock down (Figure 5C and 5D). 
In addition, HIF-1/2 alpha negative CSC maintained 
the CSC markers Oct4-A, Vimentin and Nanog, lost by 
control cells during endothelial differentiation (Figure 5E).
Effect of Sunitinib and sFlk on endothelial 
differentiation of CSC in vivo
CSC injected subcutaneously in SCID mice 
organized after 7 days in small clusters of few cells 
and, after 14 days, in highly vascularized tumors 
(Supplementary Figure 3A and 3B and Figure 6A and 
6B). At an early tumor phase, vessels were mainly of 
murine origin, as endothelial cells did not express HLA 
(Supplementary Figure 3C and 3D). At variance, in 
large tumors, some intratumor vessels were of human 
origin, as detected by human HLA Class I and vWF 
co-expression (Figure 7B and 7C). This is possibly 
related to the detection of hypoxic areas in large tumors 
that showed a strong expression of the hypoxic marker 
carbonic anhydrase IX (CAIX). Small tumor clusters did 
not express CAIX (Supplementary Figure 3E and 3F). 
We therefore evaluated the possible differential effect 
of VEGF or tyrosine kinase blockade on endothelial 
differentiation of CSC in vivo after 14 days. SCID mice 
were treated as follows: (i) mice injected subcutaneously 
with B-CSC expressing the soluble VEGF trap sFlk1 
(sFLK1 mice), (ii) mice injected subcutaneously with 
B-CSC transduced with an empty vector as control (Ctl 
mice), (iii) mice injected subcutaneously with control 
B-CSC and daily treated with oral administration of 
Sunitinib (50 mg/kg, SUN mice). Tumors generated 
by sFLK1 cells, in which the released sFlk1 is able to 
sequester human and murine VEGF, showed reduced 
growth and vascularization and extensive necrosis 
(Figure 6A and 6B). The analysis of the vessels showed 
co-existence of both β2-microglobulin+ murine vessels 
and vWF+/HLA+ human vessels (Figure 7A–7C). 
In SUN mice, tumors generated by B-CSC showed 
reduced growth and vascularization and extensive necrosis 
comparable to that in sFLK1 mice (Figure 6A and 6B). 
The murine vessels in SUN tumors were reduced in 
respect to Ctl to an extent similar to sFLK1 tumors. 
However, the number of human vessels detected was 
almost negligible, and the great percentage of vessels 
observed was of murine origin (Figure 7A–7C). These 
data indicate that in vivo endothelial differentiation of 
B-CSC, i.e. vasculogenesis, is independent of VEGF 
inhibition by sFlk1, but dependent on endothelial receptor 
tyrosine blockade by Sunitinib. Finally, we evaluated 
the presence of pericytes around the vessels of treated 
tumors, as a sign of vascular stability. In SUN and sFLK1 
tumors, the few vessels detectable were covered by 
α-SMA+ (Figure 7C) cells. At variance, vessels detected 
in Ctl mice within the tumor were mainly negative 
(Figure 7C). These results altogether may suggest that 
the anti-angiogenic treatment using both Sunitinib and 
VEGF blockade reduces tumor vascularization while 
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it stabilizes the surviving vessels, as reported [19]. 
Moreover, Sunitinib could specifically block tumor 
CSC-dependent vasculogenesis.
DISCUSSION
In the present study, we investigated the effect 
of drugs targeting the VEGF pathway on tumor 
vasculogenesis. The results show a differential effect 
of anti-VEGF drugs and Sunitinib on CSC-induced 
vasculogenesis. VEGF blockade only affected differentiated 
endothelial cells in vitro and murine angiogenesis in vivo, 
respectively. At variance, Sunitinib also impaired the 
process of differentiation of CSC into endothelial cells 
in vitro and the CSC-induced vasculogenesis in vivo.
Tumor vascularization is granted by combined 
mechanisms of angiogenesis and vasculogenesis, and anti-
tumor therapies should ideally affect both. We here found 
that Sunitinib and Bevacizumab displayed a cytotoxic and 
anti-proliferative response on endothelial cells derived 
from CSC that was comparable to the response of the 
total endothelial tumor population. A similar inhibitory 
Figure 5: Effect of Sunitinib on HIF pathway during CSC endothelial differentiation. Panel A. Quantitative RT-PCR analysis 
showing the increase of HIF-1 alpha but not of HIF-2 alpha by B-CSC incubated for 3 hours in endothelial-differentiating condition in hypoxia 
in the presence and absence of 1 μM Sunitinib (S1) or 100 μg/ml Bevacizumab (B100). Data were normalized to GAPDH mRNA and to 1 for 
time 0, expressed as relative quantification (RQ) and are mean ± SD of three different experiments. Student’s t test was performed: **= p < 
0.001 vs Basal; $= p < 0.001 vs Hypoxia. Panel B. Western blot micrograph and densitometric analysis of HIF-1 alpha expression. Data, shown 
as arbitrary units, are representative of three different experiments and were normalized to vinculin expression. Student’s t test was performed: 
**= p < 0.001 vs Basal; $= p < 0.001 vs CTL. Panel C and D. Expression of endothelial differentiation markers by control B-CSC infected 
with a scramble shRNA (shCTL) and in B-CSC lacking HIF-1 alpha (shHIF-1α), HIF-2 alpha (shHIF-2α) or both (shHIF-1α+shHIF-2α). 
In the representative FACS analyses, the gray filled area shows binding of the specific antibody and the dark line the isotypic control (C). In 
the histogram, the percentage of expression is reported (D). Data are mean ± SD of five different experiments. Student’s t test was performed: 
**= p < 0.001 vs shCTL. Panel E. Quantitative RT-PCR analysis showing the reduction of the stem-cell associated markers Oct4-A, Vimentin 
and Nanog in shCTL cells after endothelial differentiation in respect to basal condition, but not in endothelial differentiated shHIF-1α+shHIF-
2α cells. Data were normalized to GAPDH mRNA and to 1 for time 0 and expressed as relative quantification (RQ). Data are mean ± SD of 
three different experiments. Student’s t test was performed: **= p < 0.001 vs Basal.
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effect was obtained by VEGF-blockade (sFlk1) and 
Sunitinib that affected the murine vessels originated in 
CSC-induced tumors in vivo. These data indicate that both 
VEGF blockade and Sunitinib can target differentiated 
endothelial cells generated either by vasculogenesis 
or angiogenic mechanisms. As previously reported for 
tumor-derived endothelial cells [20], the sensitivity to 
anti-angiogenic drugs of CSC-derived endothelial cells 
was lower than that of normal endothelial cells, underlying 
possible mechanisms of drug resistance.
In this study, we also evaluated the effect of anti-
angiogenic drugs on CSC endothelial differentiation 
in hypoxic condition, as CSC were mainly located in 
an hypoxic perivascular niche, in close association 
to tumor vessels [21], where hypoxia may promote 
CSC differentiation [10, 22]. Interestingly, we found a 
differential effect of drugs acting through VEGF receptor 
blockade (Sunitinib and anti-VEGFR2 blocking antibody) 
in respect to those acting through VEGF inhibition 
(Bevacizumab and the VEGF soluble trap sFlk1) on CSC 
differentiation. Only Sunitinib, and not Bevacizumab 
or sFlk1, inhibited the ability of CSC to differentiate 
into endothelial cells in vitro or to organize into vessels 
in vivo. A similar effect was observed with VEGFR2 
and not VEGFR1 inhibition underlying the importance 
of the VEGFR2 receptor activation. Several possibilities 
may explain this difference between VEGFR2 and 
VEGF blockade on CSC differentiation. For instance, 
VEGFR2 might be trans-activated at an intracellular 
level, possibly by lipid metabolites, cytokine receptors 
and Plexin-A4 [23–27]. Similarly, we found that VEGFR2 
was phosphorylated in endothelial differentiated CSC even 
when VEGF was inhibited by the constant release of the 
sFlk1 VEGF trap, suggesting a possible role for VEGFR2 
activation in the absence of VEGF binding.
The effect of Sunitinib could also be explained by 
targeting of different VEGF-unrelated receptor tyrosine 
kinases such as CD140, CD117, and RET [28]. However, 
its activity in renal and breast CSCs appears dependent 
on VEGFRs, as the others receptors are absent in both 
undifferentiated and endothelial differentiated CSC. 
Finally, Sunitinib may directly act on intracellular targets, 
such as Akt or HIF. In colon cancer cells, Sunitinib was 
shown to inhibit the HIF-1 alpha translation accompanied 
Figure 6: Effect of sFlk1 and Sunitinib on tumor growth and vascularization. Tumors were generated by subcutaneous 
implant of B-CSC carrying an empty vector (Ctl) or a sFlk1 vector (sFLK1) (n = 8 per experimental group). Selected animals carrying 
Ctl tumors were treated daily with Sunitinib (SUN) from day 4. Panel A. Reduction of tumor volume and vascularization in sFLK1 and 
SUN tumors in respect to Ctl. Vessels quantification is the mean ± SD erythrocyte containing structures/field in at least 10 fields per tumor. 
Student’s t test was performed: **= p < 0.001, *= p < 0.05 vs Ctl. Panel B. Representative micrographs of tumor sections stained with 
hematoxylin and eosin (upper panels) or with Masson’s trichromic reaction (blu: connective, red: cells, yellow: erythrocytes; lower panels). 
The star indicated necrotic areas and the arrows vessels. Original magnification: H/H: 100x; Trichromic: 200x.
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Figure 7: Effect of sFlk1 and Sunitinib on murine and human tumor vessels. Panel A. Both sFlk1 releasing tumors (sFLK1) 
and Sunitinib treated tumors (SUN) showed reduction of murine vessels in respect to control tumors (Ctl), evaluated as murine β2-
microglobuline-positive structures by immunohistochemistry (n = 8 per experimental group). Murine vessels only represented a part of total 
vessels in Ctl and sFLK but not in SUN tumors. Data are the mean ± SD of β2-microglobulin positive structures containing erythrocytes 
(β2+)/field or total erythrocytes containing structures in at least 10 fields per tumor. Student’s t test was performed: **= p < 0.001, *= p 
< 0.05 vs Ctl; $$= p < 0.001, $= p < 0.05 vs β2+/field. Panel B. SUN tumors and not sFLK1 tumors showed reduction of human vessels, 
evaluated as structures co-expressing vWF and human HLA Class I (vWF+/HLA+) by immunofluorescence. Data are the mean ± SD of 
vWF+/HLA+ structures/field in at least 10 fields per tumor. Student’s t test was performed: **= p < 0.001 vs Ctl. Panel C. Representative 
micrographs of Ctl, sFLK1 and SUN tumor sections showing murine β2-microglobulin positive structures (upper panels). Representative 
micrographs of Ctl, sFLK1 and SUN tumor sections showing positive immunofluorescence staining for vWF (red) /human HLA class-I 
(green) positive structures, for human CD31 (hCD31, red) or for vWF (red)/αSMA (green). Original magnification: x200 (upper panels) 
and x400 (lower panels).
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with inactivation of Akt, possibly suggesting that Sunitinib 
may directly act on Akt [30, 31]. However, no effect on 
Akt activation was observed in our setting. In addition, 
in neuroblastoma cells, Sunitinib was reported to block 
HIF activation independently of receptor tyrosine kinase 
inhibition [32]. We similarly found that HIF-1 alpha 
synthesis, required for CSC endothelial differentiation under 
hypoxia, was inhibited by Sunitinib, although we cannot 
distinguish between a direct or a cytokine-dependent effect. 
In fact, HIF may be activated both directly and indirectly 
by tyrosine kinase-dependent intracellular pathways [29].
Regardless the mechanism involved, the specific role 
of Sunitinib on CSC endothelial differentiation supports 
its role in tumor therapy. Indeed, although Sunitinib did 
not directly affect CSC, it blocked both the angiogenesis 
and the hypoxia-driven CSC vasculogenesis, leading 
to tumor necrosis and inhibition of its development. On 
the other side, some possible negative consequences of 
the observed effects of Sunitinib can be envisaged. The 
first is a role in the maintenance of an undifferentiated 
CSC population, as shown by the maintenance of stem 
cell markers by Sunitinib treated CSC. Indeed, it was 
recently described that Sunitinib may promote embryonic 
stem cell self-renewal and limit their differentiation, 
even in the presence of established differentiating factors 
[33]. In addition, tumor hypoxia possibly induced by 
anti-angiogenic therapy itself may sustain mechanisms 
of adaptation that promote tumor progression to greater 
malignancy or increased tumor cell invasion [34–37].
In conclusion, our data indicate that VEGF inhibition 
may only affect fully differentiated endothelial cells, 
while Sunitinib, possibly through VEGFR blockade, is 
also able to impair CSC-dependent tumor vasculogenesis 
under hypoxia. As hypoxia induced by the anti-angiogenic 
therapy itself may promote tumor angiogenesis and 
vasculogenesis, the limitation of the mechanisms of CSC 
endothelial differentiation are required for its efficacy.
METHODS
Cancer stem cell isolation and characterization
Breast cancer stem cells (B-CSC) and renal cancer 
stem cells (R-CSC) were isolated, cloned, and characterized 
as previously described [15, 16; 38–41; Supplementary 
Table 1]. Briefly, B-CSC were obtained from a specimen of 
a lobular-infiltrating carcinoma obtained from a consenting 
patient according to the Ethics Committee of the S. Giovanni 
Battista Hospital of Torino, Italy, as previously described 
[16]. B-CSC were isolated and expanded as mammospheres 
in 10 ng/ml basic fibroblast growth factor (bFGF), 20 ng/ml 
epidermal growth factor (EGF), 5 μg/ml insulin and 
0.4% bovine serum albumin (all from Sigma-Aldrich), 
as previously described [40]. R-CSC were obtained from 
specimens of renal carcinomas from patients undergoing 
radical nephrectomy. CD105+ R-CSC were cultured in 
the presence of the expansion medium, a modification 
of that described for multipotent adult progenitor cells 
[42], consisting of DMEM LG (Invitrogen), with insulin-
transferrin-selenium, 10–9 M dexametasone, 100 U penicillin, 
1000 U streptomycin, 10 ng/ml EGF (all from Sigma-
Aldrich) and 5% fetal calf serum (FCS) (Sigma-Aldrich). 
A CD105+ clonal renal cancer stem cell line was selected 
and used for all the experiments. B-CSC and R-CSC were 
characterized as tumor stem cells due to the following 
criteria, previously described for cancer stem cells present 
in other tumor types [43]: 1) were clonogenic, 2) expressed 
stem cell markers and lacked differentiative markers, 3) could 
differentiate in vitro into epithelial and endothelial cell types, 
and 4) could generate in vivo serially transplantable tumors. 
These tumors, despite being derived from clones expressing 
mesenchymal markers, were epithelial carcinomas as the 
tumor of origin [15, 16, 39; Supplementary Table 1].
Human umbilical vein endothelial cells (HUVEC) 
were obtained and characterized as previously described 
[44]. A tumor endothelial cell line (BTEC) obtained from a 
breast tumor was previously isolated and characterized [45].
Anti-angiogenic drugs
Sunitinib malate (Sigma-Aldrich) and Bevacizumab 
(Genentech) were stocked according to the manufacturer’s 
instructions.
Epithelial and endothelial differentiation of 
CSC in vitro
Epithelial differentiation was obtained in the presence 
of RPMI plus 10% FCS, without the addition of growth 
factors, as previously described [15, 16]. For endothelial 
differentiation, B-CSC and R-CSC were plated into 6-well 
culture plated coated with Endothelial Cell Attachment 
Factor (Sigma-Aldrich), in Endogro (Merck Millipore) 
without growth factor supplement and maintained in 
hypoxia (1% O2 and 5% CO2) in hypoxia chambers (Stem 
Cells Technologies) for 14 days. The anti-angiogenic 
drugs (Sunitinib 1 μM, Bevacizumab 100 μg/ml) and the 
anti-VEGFR1 or anti-VEGFR-2 blocking polyclonal Ab, 
or an irrelevant rabbit serum (all from R&D Systems), all 
at 0.2 μg/ml, were added to cell cultures under hypoxic 
differentiation at day 0 and every three days thereafter.
Proliferation and survival
DNA synthesis was detected as incorporation 
of 5-bromo-2-deoxyuridine (BrdU) using an enzyme-
linked immunosorbent assay kit (Chemicon) after 48 
hours of treatment. To evaluate cell death, supernatants 
containing detached and death cells were and cells were 
trypsinized. Cell suspensions were stained with 100 μg/
ml propidium iodide in PBS containing 0.1% Triton. 
Cell cycle distribution was determined using a Beckton 
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Dickinson FACScan flow cytometer, analysing 10000 cells 
per sample, and the percentage of cells in sub-G1 phase 
(apoptotic cells) was estimated.
Tubulogenesis
In vitro formation of capillary-like structures 
was done on growth factor–reduced Matrigel (BD 
Biosciences). After hypoxia-induced endothelial 
differentiation, cells (3 × 104 cells per well) were seeded 
onto Matrigel-coated wells in RPMI plus 5% FCS 
with or without Sunitinib or Bevacizumab. Cells were 
periodically observed with a Nikon inverted microscope 
and experimental results recorded after 18 hours. Image 
analysis was performed with the MicroImage analysis 
system (Cast Imaging srl).
Western blot analysis
Cells were lysed in RIPA buffer supplemented with 
protease and phosphatase inhibitor cocktail and PMSF 
(Sigma-Aldrich). Aliquots of the cell lysates containing 
50 μg protein, as determined by the Bradford method, 
were run on 8% SDS-PAGE under reducing conditions 
and blotted onto PVDF membrane filters using the 
iBLOT system (Life Technologies). For Western blot 
analysis, anti-HIF-1 alpha, anti-vinculin, anti-actin 
(all from Santa Cruz Biotechnology), anti-AKT or anti 
p-AKT(Ser473) (both from Cell Signalling) Abs were 
used. sFlk1 expression was tested in the supernatant of 
B-CSC maintained in culture in absence of serum for 24 h. 
After centrifugation to remove the cell debris, cell-free 
supernatants were concentrated 25-fold by centrifugation 
using Ultra-PL 3 ultrafiltration units (Amicon-Ultra, 
Millipore) with a 3-kDa molecular weight cut off and 
Western blot performed using the anti-Flk1 Ab (R&D 
Systems). For immuonoprecipitation studies, 10 μg of 
anti-Flk1 antibody (R&D Systems) was coupled with 
1.5 mg Dynabeads-Protein G (Life Technologies) in 
order to precipitate 1 mg of cell lysates, according to 
manufacturer’s instructions. The immunoprecipitated 
samples were immediately processed for electrophoresis 
and Western blot analysis, using anti-VR2 (R&D Systems) 
and anti p-VR2 (Tyr951) (Santa Cruz Biotechnology). 
Differences in protein phosphorylation were evaluated as 
VR2/p-VR2 (Tyr951) ratio.
RNA isolation and real time PCR
Total RNA was isolated using Trizol Reagent 
(Ambion) according to the manufacturer’s protocol, and 
quantified spectrophotometrically (Nanodrop ND-1000). 
For gene expression analysis, quantitative real-time PCR 
was performed. Briefly, first-strand cDNA was produced 
from 200 ng of total RNA using the High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems).
Quantitative Real-time PCR experiments were 
performed in 20-μl reaction mixture containing 5 ng of 
cDNA template, the sequence-specific oligonucleotide 
primers (purchased from MWG-Biotech) and the Power 
SYBR Green PCR Master Mix (Applied Biosystems). 
GAPDH was used to normalize RNA inputs. Fold change 
expression respect to control was calculated for all 
samples. The sequence-specific oligonucleotide primers 
are available in the Supplementary Materials.
Generation of HIF−/− CSC and of sFLK1 CSC
For knock down of HIF-1 alpha and HIF-2 alpha, 
a pGIPZ lentiviral vector (Open Biosystems) carrying 
shRNA against HIF-1 alpha, HIF-2 alpha or scramble 
was used (see Supplementary Materials). The constructs 
were then transfected with the 293T cell line using the 
ViraPower Packaging Mix (Life Technologies) for 
lentiviruses production. After titering the lentiviral stock, 
CSC were transduced with lentiviral particles following 
the manufacturer’s instructions. Cells were selected by 
puromycin (Gibco) (250 ng/ml) and antibiotic-resistant 
cells were expanded. Cell infection was evaluated by 
GFP+ > 90%, as assessed by FACS analysis, and by down 
regulation of the target gene > 60% by quantitative RT-
PCR. CSC silenced for HIF-1 or 2 alpha significantly 
reduced both HIF isoforms as compared to control cells 
(Supplementary Figure 2).
For the generation of sFLK1 B-CSC, we used a 
lentiviral vector carrying the sequence of the soluble 
form of the VEGFR2 receptor (sFlk1) under the control 
of the CMV promoter, and an empty vector as a control 
as described [29]. Cell infection was evaluated by 
the presence of the soluble form of VEGFR2 on the 
supernatant of B-CSC by western blot (Figure 4B).
In vivo experiments
To evaluate the vasculogenic potential of B-CSC, 
4 × 105 cells were implanted subcutaneously into SCID 
mice (Charles River) within Growth Factor–Reduced 
Matrigel (BD Biosciences). The effect of VEGF blockade 
on vasculogenesis was studied by using B-CSC infected 
with a soluble Flk1 lentivirus (sFLK1 cells), able to bind 
both human and murine VEGF (Figure 4B). Briefly, 
4 × 105 cells infected with lentiviruses carrying the 
empty vector (Ctl) or the sFlk1 vector (sFLK1) were 
resuspended in 50 μl DMEM plus 150 μl of Matrigel 
at 4°C. Cells were injected subcutaneously into the left 
back of SCID mice (n = 12 for the Ctl group, n = 8 for 
the sFLK1). In addition, a group of animals injected 
with 4 × 105 cells infected with lentiviruses carrying the 
empty vector (Ctl) were orally treated with Sunitinib 
(50 mg/kg) starting from day four after cell injection 
(n = 8). After 7 or 14 days, mice were sacrificed, and 
tumors recovered and processed for histology.
Oncotarget11307www.impactjournals.com/oncotarget
Immunohistochemistry and immunofluorescence
Sections from paraffin-embedded blocks of tumors 
obtained from SCID mice were stained with hematoxilyn 
and eosin or with Trichromic Masson reaction (BioOptica) 
to detect vessels, or with an anti-mouse β2-microglobulin 
Ab, (Santa Cruz), or with anti-Carbonic Anhydrase IX 
(CAIX) Ab (Novus Biologicals). At least 10 pictures/
tumor were taken at a 200X magnification. Vessel count 
was performed in blind on Masson’s trichromic or 
murine β2-microglobulin stained sections and expressed 
as number of structures with red blood cells/field. 
Immunofluorescence was performed on cells cultured 
on chamber slides (Nunc) using the following Abs: 
anti-von Willebrand Factor (vWF) Ab (Dako), anti-pan-
cytokeratin (CK) Ab (Biomeda), VE-Cadherin (VE-Cad) 
Ab (Merck Millipore). Immunofluorescence was also 
performed on cryostatic sections for HLA-class I Ab, for 
vWF (BioLegend), human CD31 (Becton Dickinson) and 
α-SMA (Sigma-Aldrich). Alexa Fluor488 or Texas Red-
conjugated anti-rabbit and anti-mouse IgG (Molecular 
Probes) were used as secondary Abs. Hoechst 33258 dye 
(Sigma-Aldrich) was added for nuclear staining. Confocal 
microscopy analysis was performed using a Zeiss LSM 
5 Pascal model confocal microscope (Carl Zeiss). For 
cytofluorimetric analysis cells were stained with the 
following fluorescein isothiocyanate, phycoerythrin or 
allophycocyanin-conjugated antibodies: CD24, CD44, 
CD140, CD31 (all from Becton Dickinson) CD105, 
VEGFR2 (both from Miltenyi Biotec), CD117 (Dako), 
TIE2, VEGFR1, VEGFR3 (all from R&D Systems). 
Isotypes (Miltenyi Biotec) were used as negative 
controls. Cells were subjected to cytofluorimetric analysis 
(FACScan Becton Dickinson).
Statistical analysis
Statistical analysis was performed by using the 
Student t test, or ANOVA with Dunnet’s or Newmann 
Keuls’ multicomparison tests, as appropriate. A p value 
of < 0.05 was considered significant.
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